Naturally Inspired | Scientifically Defined

Specialist in plant derived cell signalling small molecules to address
challenging medical conditions for humans and companion animals

QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®

27 April 2020

Australian life sciences company, QBiotics Group Limited (QBiotics) has commercialised the first product for its lead compound, tigilanol tiglate, with the launch of STELFONTA® in the European markets at the Virbac Oncology Summit Webinar Event (24 April 2020).

STELFONTA® (tigilanol tiglate) is now available as the first pharmaceutical treatment for all grades of canine non-metastatic mast cell tumours (MCT).1 MCTs are the second most frequent cancer diagnosed in dogs and the most common skin cancer, accounting for up to 21% of skin cancer cases.2
 
PDF documentRead the full media release